Affordable Access

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.

Authors
  • Chahine, Elias B1
  • Sucher, Allana J2
  • Hemstreet, Brian A2
  • 1 Palm Beach Atlantic University, West Palm Beach, FL, USA [email protected]
  • 2 Regis University, Denver, CO, USA.
Type
Published Article
Journal
Annals of Pharmacotherapy
Publisher
SAGE Publications
Publication Date
Sep 08, 2016
Identifiers
PMID: 27609942
Source
Medline
Keywords
License
Unknown

Abstract

Sofosbuvir/velpatasvir is safe and effective to treat HCV genotypes 1, 2, 3, 4, 5, and 6 in patients with or without compensated cirrhosis. The addition of ribavirin is recommended in patients with decompensated cirrhosis.

Report this publication

Statistics

Seen <100 times